<DOC>
	<DOCNO>NCT00003342</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase I trial study side effect give gemcitabine , doxorubicin , paclitaxel together carboplatin treat patient advanced bladder kidney cancer impair kidney function .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Bladder Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity dose-dense carboplatin plus paclitaxel weekly schedule give sequence gemcitabine doxorubicin patient renal impairment metastatic locally advanced transitional cell carcinoma urothelium . - Observe outcome sequential systemic chemotherapy patient , follow surgical resection adjuvant therapy patient poor renal function precludes use cisplatin-based chemotherapy . OUTLINE : This dose escalation study carboplatin . Patients receive gemcitabine IV 10 minute doxorubicin IV 15 minute 5 dos week 1 , 3 , 5 , 7 , 9 . Filgrastim ( G-CSF ) give subcutaneously day 3 10 2-week course . On week 11 , patient receive paclitaxel carboplatin IV 1 hour weekly 12 week . Each cohort 3 patient enter sequentially increase dos carboplatin . If patient experience dose limit toxicity ( DLT ) , 6 patient enter dose level . If 3 patient experience DLT dose level , maximum tolerate dose surpass total 6 patient treat previous level . Patients evaluate week 16 end study . PROJECTED ACCRUAL : There 18-30 patient accrue study 9-15 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced transitional cell urothelial cancer Clinical Stage IV : T , N13 , M0 ; T , N , M1 ; cT4 , Nx , M0 ( bladder tumor ) Pathological Stage III IV bladder cancer : T , N13 , M0 ; T3b , N0 , M0 ; T4 , N0 , M0 ; T4 , Nx , M0 Pathological Stage III IV urothelial cancer renal pelvis ureter : T , N13 , M0 ; T3 , N0 , M0 ; T4 , N0 , M0 ; surgery perform within 10 week initiation therapy Impaired renal function ( See Renal function test ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % OR ECOG 01 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin le 1.5 time normal Alkaline phosphatase less 2 time normal SGOT le 2 time normal Renal : Creatinine great 1.5 mg/dL great 2.5 mg/dL OR Creatinine clearance 3059 mL/min Cardiovascular : Normal cardiac function history , physical examination , chest radiograph OR If prior cardiac disease , leave ventricular ejection fraction must least 50 % radionuclide ventriculogram echocardiogram No serious cardiac arrhythmia ; include first , second , third degree heart block No New York Heart Association class III IV heart disease Other : No uncontrolled infection No active cancer , except nonmelanomatous skin cancer situ carcinoma cervix curatively treat Not pregnant Effective barrier contraception require fertile patient 6 month therapy ( encourage continue 2 year longer ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy bladder At least 4 week since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>localize transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>